Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDX 301

X
Drug Profile

CDX 301

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics; Mobista; rhuFlt3L; Vaccine-adjuvant-Amgen; Vaccine-adjuvant-Celldex-Therapeutics; Vaccine-adjuvant-FLT-3-ligand; Vaccine-adjuvant-Immunex

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Dana-Farber Cancer Institute; Icahn School of Medicine at Mount Sinai; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antiretrovirals; Cytokines; Immunotherapies; Recombinant proteins
  • Mechanism of Action Fms-like tyrosine kinase 3 stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II B-cell lymphoma; Breast cancer; Head and neck cancer; Non-Hodgkin's lymphoma
  • Phase I Malignant melanoma; Prostate cancer; Triple negative breast cancer
  • No development reported HIV infections; Lymphoma; Solid tumours
  • Discontinued Autoimmune disorders; Infections; Stem cell mobilisation

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for preclinical development in HIV-infections in USA
  • 21 Nov 2023 Washington University School of Medicine, in collaboration with Celldex Therapeutics and The Foundation for Barnes-Jewish Hospital terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (IV; infusion) due to Celldex decision (NCT04536077)
  • 23 Jun 2023 Albert Einstein College of Medicine and Celldex Therapeutics terminates phase I/II trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA due to low accural (Parenteral) (NCT04491084)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top